Drug/Small Molecule:

terazosin

Terazosin is a selective alpha 1 antagonist used for treatment of symptoms of prostate enlargement (BPH). It also acts to lower blood pressure, so it is a drug of choice for men with hypertension and prostate enlargement. It works by blocking the action of adrenaline on smooth muscle of the bladder and the blood vessel walls. (source: Drug Bank)

For the treatment of symptomatic benign prostatic hyperplasia (BPH) and also for hypertension. (source: Drug Bank)

Terazosin selectively and competitively inhibits vascular postsynaptic alpha(1)-adrenergic receptors, resulting in peripheral vasodilation and a reduction of vascular resistance and blood pressure. Unlike the nonselective alph-adrenergic blockers phenoxybenzamine and phentolamine, terazosin does not block presynaptic alpha(2)-receptors and, hence, does not cause reflex activation of norepinephrine release to produce reflex tachycardia. (source: Drug Bank)

Terazosin, classified as a quinazoline, is similar to doxazosin and prazosin. As an alpha-adrenergic blocking agent, terazosin is used to treat hypertension and benign prostatic hypertrophy (BPH). Terazosin produces vasodilation and reduces peripheral resistance but in general has slight effect on cardiac output. Antihypertensive effect with chronic dosing is usually not accompanied by reflex tachycardia. (source: Drug Bank)

Hepatic. One of the four metabolites identified (piperazine derivative of terazosin) has antihypertensive activity. (source: Drug Bank)

90-94% (source: Drug Bank)

Essentially completely absorbed in man (90% bioavailability). (source: Drug Bank)

LD₅₀=259.3mg/kg (i.v. in mice) (source: Drug Bank)

COc1cc2c(cc1OC)nc(nc2N)N3CCN(CC3)C(=O)C4CCCO4 (source: Drug Bank)